NCT05800366 2026-03-05A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaDana-Farber Cancer InstitutePhase 2 Recruiting41 enrolled
NCT04479267 2025-09-29Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaBarbara Ann Karmanos Cancer InstitutePhase 2 Active not recruiting8 enrolled